Gland Pharma Secures Global Regulatory Backing with Danish GMP and US FDA Approvals

has achieved a key milestone as its Pashamylaram facility received GMP compliance certification from the Danish regulator, reinforcing its manufacturing quality for aseptically prepared powder formulations. Adding to this, the Visakhapatnam facility, inspected by the US FDA in Dec 2024, was issued an EIR on June 24, 2025, with its CAPA plan fully accepted and no disruption to operations. These regulatory wins not only boost export readiness but also strengthen investor confidence by demonstrating Gland’s capability to meet stringent international standards across major markets. Follow me for more such updates, Thank You! Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.